Zemdri
| Chemical Name | plazomicin |
| Dosage Form | Injection (intravenous; 50 mg/mL containing plazomicin sulfate equivalent to 500 mg plazomicin free base) |
| Drug Class | Antibacterials |
| System | Urinary |
| Company | Cipla USA |
| Approval Year | 2018 |
Indication
- Zemdri is indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis.